计算溶液所需的质量、体积或浓度。
活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
M129684-10mg |
10mg |
现货 ![]() |
| |
M129684-50mg |
50mg |
现货 ![]() |
| |
M129684-100mg |
100mg |
现货 ![]() |
|
英文别名 | 1032350-13-2 | MFCD14584463 | 4-[[(2S,4R)-5-Ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid calcium salt | AC-28437 | J-000912 | MK 2206 dihydrochloride | 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]nap |
---|---|
规格或纯度 | Moligand™, ≥98% |
英文名称 | MK-2206 2HCl |
生化机理 | MK-2206 2HCl 是 Akt1、Akt2 和 Akt3 的高选择性抑制剂,IC50 值分别为 8 nM、12 nM 和 65 nM。MK-2206 是一种异构抑制剂,由 pleckstrin 同源结构域激活。MK-2206 可抑制 Akt T308 和 S473 的自动磷酸化。MK-2206 还能阻止 Akt 介导的下游信号分子磷酸化,包括 TSC2、PRAS40 和核糖体 S6 蛋白。在肺癌 NCI-H460 或卵巢癌 A2780 肿瘤细胞中,MK-2206 还能与厄洛替尼或拉帕替尼等细胞毒性药物联用,产生协同效应。 |
应用 | A highly selective pan-Akt inhibitor activated by the pleckstrin homology domain |
储存温度 | -20°C储存,充氩 |
运输条件 | 超低温冰袋运输 |
作用类型 | 变构调节剂 |
作用机制 | AKT 丝氨酸/苏氨酸激酶 1 的变构调节剂;AKT 丝氨酸/苏氨酸激酶 2 的变构调节剂;AKT 丝氨酸/苏氨酸激酶 3 的变构调节剂 |
产品介绍 |
MK-2206 2HCl是一种高度选择性的Akt1/2/3抑制剂,IC50分别为8 nM/12 nM/65 nM;对250种其他蛋白激酶没有抑制活性。A highly selective pan-Akt inhibitor activated by the pleckstrin homology domain MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM, respectively; no inhibitory activities against 250 other protein kinases observed. |
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504770874 |
---|---|
分子类型 | 未知 |
IUPAC Name | 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one;dihydrochloride |
INCHI | InChI=1S/C25H21N5O.2ClH/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31;;/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31);2*1H |
InChi Key | HWUHTJIKQZZBRA-UHFFFAOYSA-N |
Canonical SMILES | C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl |
Isomeric SMILES | C1CC(C1)(C2=CC=C(C=C2)C3=C(C=C4C(=N3)C=CN5C4=NNC5=O)C6=CC=CC=C6)N.Cl.Cl |
PubChem CID | 46930998 |
分子量 | 480.39 |
溶解性 | Soluble in DMSO (≥92 mg/ml), water (≥92 mg/ml), ethanol (≥1.8 mg/ml), and methanol. |
---|---|
敏感性 | 对湿度敏感 |
熔点 | >225°C |
分子量 | 480.400 g/mol |
XLogP3 | |
氢键供体数Hydrogen Bond Donor Count | 4 |
氢键受体数Hydrogen Bond Acceptor Count | 4 |
可旋转键计数Rotatable Bond Count | 3 |
精确质量Exact Mass | 479.128 Da |
单同位素质量Monoisotopic Mass | 479.128 Da |
拓扑极表面积Topological Polar Surface Area | 83.600 Ų |
重原子数Heavy Atom Count | 33 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 760.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 3 |
1. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS et al.. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.. Mol Cancer Ther, 9 (7): (1956-67). [PMID:20571069] [10.1021/op500134e] |
2. Liu R, Liu D, Trink E, Bojdani E, Ning G, Xing M. (2011) The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.. J Clin Endocrinol Metab, 96 (4): (E577-85). [PMID:21289267] [10.1021/op500134e] |
3. Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC. (2015) The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells.. Naunyn Schmiedebergs Arch Pharmacol, 388 (1): (19-31). [PMID:25164962] [10.1021/op500134e] |
4. Holland WS, Chinn DC, Lara Jr PN, Gandara DR, Mack PC. (2015) Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.. J Cancer Res Clin Oncol, 141 (4): (615-26). [PMID:25323938] [10.1021/op500134e] |